Imitrex vs. Ajovy
See how Imitrex and Ajovy compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Imitrex treats a migraine attack after it starts, while Ajovy is taken on a regular schedule to prevent migraines before they begin.
Imitrex works within hours as a tablet, injection, or nasal spray, while Ajovy is injected once a month or once every three months.
Imitrex carries cardiovascular warnings that Ajovy does not, while Ajovy commonly causes injection site reactions and rarely serious allergic reactions.
Imitrex vs. Ajovy Drug Summary
Imitrex
Imitrex (sumatriptan) is a triptan that narrows blood vessels and blocks pain signals during a migraine attack. It is taken as a tablet, injection, or nasal spray at the first sign of a migraine, with a repeat dose allowed after two hours if needed. It treats migraine and cluster headache attacks but does not prevent future migraines.
Ajovy
Ajovy (fremanezumab-vfrm) is a CGRP monoclonal antibody used to prevent migraines before they start rather than treat an attack in progress. It is given as a subcutaneous injection either once a month or as a larger dose once every three months. It is approved for adults and for adolescents 6 to 17 who weigh at least 45 kg.
Imitrex vs. Ajovy Side Effects
Imitrex
Ajovy
Imitrex vs. Ajovy Dosage
Imitrex
Ajovy
| STAGE | DOSE | WHEN |
| Starting dose | 25 mg, 50 mg, or 100 mg | At the start |
| Maximum dose | Repeat dose, max 200mg/day | If needed |
| Dose changes | 1 increase | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 225 mg once monthly | At the start |
| Maximum dose | 675 mg every 3 months | If needed |
| Dose changes | 1 increase | As tolerated |
Imitrex
| STAGE | DOSE | WHEN |
| Starting dose | 25 mg, 50 mg, or 100 mg | At the start |
| Maximum dose | Repeat dose, max 200mg/day | If needed |
| Dose changes | 1 increase | As tolerated |
Ajovy
| STAGE | DOSE | WHEN |
| Starting dose | 225 mg once monthly | At the start |
| Maximum dose | 675 mg every 3 months | If needed |
| Dose changes | 1 increase | As tolerated |
Imitrex vs. Ajovy Indications
Imitrex
Imitrex is FDA-approved for the acute treatment of migraine attacks with or without aura in adults, and the injectable form also treats cluster headache. It is taken only when a migraine starts, not on a daily schedule. It is not approved to prevent migraines or for use in children.
Acute migraine treatment in adults
Cluster headache treatment (injection only)
Taken at onset of migraine symptoms
Not approved for migraine prevention
Not approved for patients under 18
Ajovy
Ajovy is FDA-approved for the preventive treatment of migraine in adults, given as a regular injection to lower how often migraines occur. It is also approved for adolescents ages 6 to 17 who weigh at least 45 kg. It is not intended to treat a migraine that has already started.
Preventive migraine treatment in adults
Preventive treatment for ages 6-17 (45+ kg)
Given monthly or every 3 months
Not approved for acute migraine attacks
No pediatric use under 6 years or 45 kg
Imitrex vs. Ajovy Pros and Cons
Imitrex
Imitrex has been used since 1992 and offers multiple delivery options for fast relief once a migraine begins. It is widely available as a generic and typically works within a couple of hours for most patients. Its cardiovascular warnings mean it is not a safe option for everyone.
Pros
Multiple forms: tablet, injection, or nasal spray
Works within hours of an attack starting
Decades of clinical use and prescribing history
Only taken when needed, not on a fixed schedule
Cons
Not effective for migraine prevention
Contraindicated with heart disease or stroke risk
Cannot combine with other triptans within 24 hours
Frequent use risks medication overuse headache
Ajovy
Ajovy targets the CGRP pathway to reduce migraine frequency over time rather than treat individual attacks. Its infrequent dosing schedule appeals to patients who want to avoid daily pills, and its safety profile has been well studied in trials. As a newer biologic, it still requires ongoing injections and carries its own risks.
Pros
Reduces migraine frequency instead of treating attacks
Only 1 injection a month or 3 every 3 months
Approved for adolescents 6 to 17 years old
Long-lasting effect from a 30-day half-life
Cons
Does not relieve a migraine once it starts
Injection site reactions are common
Risk of rare hypersensitivity reactions
No generic version currently available
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.